138P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC): RATIONALE-304 updated analysis. (December 2022) - Lu, S.; Wang, J.; Yu, Y.; Yu, X.; Hu, Y.; Ma, Z.; Li, X.; He, W.; Bao, Y.; Wang, M.